Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-89387.09%
operating margin TTM
-99018.54%
revenue TTM
515.00 Thousand
revenue per share TTM
0.01$
valuation ratios | |
|---|---|
| pe ratio | -3.26 |
| peg ratio | -0.78 |
| price to book ratio | 1.31 |
| price to sales ratio | 3,492.79 |
| enterprise value multiple | -4.26 |
| price fair value | 1.31 |
profitability ratios | |
|---|---|
| gross profit margin | -1931.79% |
| operating profit margin | -99018.54% |
| pretax profit margin | -89387.09% |
| net profit margin | -89387.09% |
| return on assets | -36.36% |
| return on equity | -43.35% |
| return on capital employed | -43.06% |
liquidity ratio | |
|---|---|
| current ratio | 15.43 |
| quick ratio | 15.43 |
| cash ratio | 2.08 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 127.48 |
| cash conversion cycle | -127.48 |
| receivables turnover | 0.00 |
| payables turnover | 2.86 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.03 |
| total debt to capitalization | 0.03 |
| interest coverage | -98.17 |
| cash flow to debt ratio | -11.01 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.43 |
| cash per share | 10.57 |
| operating cash flow per share | -3.42 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -11.01 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -454.64 |
Frequently Asked Questions
When was the last time Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported earnings?
Viridian Therapeutics, Inc. (VRDN) published its most recent earnings results on 12-11-2024.
What is Viridian Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Viridian Therapeutics, Inc. (NASDAQ:VRDN)'s trailing twelve months ROE is -43.35%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Viridian Therapeutics, Inc. (VRDN) currently has a ROA of -36.36%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did VRDN's net profit margin stand at?
VRDN reported a profit margin of -89387.09% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is VRDN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 15.43 in the most recent quarter. The quick ratio stood at 15.43, with a Debt/Eq ratio of 0.03.